Biochemist Joanne Lemieux worked with three other U of A researchers on a new study showing that a drug that cures deadly peritonitis in cats also works well enough against the coronavirus that causes COVID-19 to fast-track it into human clinical trials. (Photo: Supplied)
Fast-tracked research leads to phase 1 clinical trials.
Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect will also be effective as a treatment for humans against COVID-19.
“In just two months, our results have shown that the drug is effective at inhibiting viral replication in cells with SARS-CoV-2,” said Joanne Lemieux, a professor of biochemistry in the Faculty of Medicine & Dentistry.
“This drug is very likely to work in humans, so we’re encouraged that it will be an effective antiviral treatment for COVID-19 patients.”
The drug is a protease inhibitor that interferes with the virus’s ability to replicate, thus ending an infection. Proteases are key to many body functions and are common targets for drugs to treat everything from high blood pressure to cancer and HIV.
First studied by U of A chemist John Vederas and biochemist Michael James following the 2003 outbreak of severe acute respiratory syndrome (SARS), the protease inhibitor was further developed by veterinary researchers who showed it cures a disease that is fatal in cats.
The work to test the drug against the coronavirus that causes COVID-19 was a co-operative effort between four U of A laboratories, run by Lemieux, Vederas, biochemistry professor Howard Young and the founding director of the Li Ka Shing Institute of Virology, Lorne Tyrrell. Some of the experiments were carried out by the Stanford Synchrotron Radiation Lightsource Structural Molecular Biology program.
Their findings were published today in the peer-reviewed journal Nature Communications after first being posted on BioRxIV, a research website.
“There’s a rule with COVID research that all results need to be made public immediately,” Lemieux said, which is why they were posted before being peer-reviewed.
She said interest in the work is high, with the paper being accessed thousands of times as soon as it was posted.
Lemieux explained that Vederas synthesized the compounds, and Tyrrell tested them against the SARS-CoV-2 virus in test tubes and in human cell lines. The Young and Lemieux groups then revealed the crystal structure of the drug as it binds with the protein.
”We determined the three-dimensional shape of the protease with the drug in the active site pocket, showing the mechanism of inhibition,” she said. “This will allow us to develop even more effective drugs.”
Lemieux said she will continue to test modifications of the inhibitor to make it an even better fit inside the virus.
But she said the current drug shows enough antiviral action against SARS-CoV-2 to proceed immediately to clinical trials.
“Typically for a drug to go into clinical trials, it has to be confirmed in the lab and then tested in animal models,” Lemieux said. “Because this drug has already been used to treat cats with coronavirus, and it’s effective with little to no toxicity, it’s already passed those stages and this allows us to move forward.”
“Because of the strong data that we and others have gathered we’re pursuing clinical trials for this drug as an antiviral for COVID-19.”
The researchers have established a collaboration with Anivive Life Sciences, a veterinary medicine company that is developing the drug for cats, to produce the quality and quantity of drug needed for human clinical trials. Lemieux said it will likely be tested in Alberta in combination with other promising antivirals such as remdesivir, the first treatment approved for conditional use in some countries including the United States and Canada.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Researchers discover molecule that can neutralise SARS-CoV-2 virus
The molecule's discovery began at the height of the pandemic, according to the study, as the team of scientists screened 15,09,984 feature-rich compounds in the UH Research Computing Data Core.
- Attacking SARS-CoV-2 Infection from a Different Front
The findings are published in Nature Communications in an article titled, “ Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2 .” “We’re attacking the virus from a ...
- Molecule neutralising SARS-CoV-2 virus found, could reduce infection duration upon exposure
The molecule's discovery began at the height of the pandemic, according to the study, as the team of scientists screened 15,09,984 feature-rich compounds ...
- ORNL-led scientists design molecule to disrupt infection mechanism of SARS-CoV-2
A molecule designed by a team of scientists led by the Department of Energy’s Oak Ridge National Laboratory could change how COVID infections are treated. The new molecule targets PLPro, which ...
- Team designs molecule to disrupt SARS-CoV-2 infection
A team of scientists led by the Department of Energy's Oak Ridge National Laboratory designed a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”SARS-CoV-2 antiviral” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- Pfizer’s COVID-19 drug Paxlovid is less effective against viral infection
Scientists showed that drug-resistant variants have appeared multiple times independently in different parts of the world, with regional clusters providing evidence for person-to-person transmission.
- Evidence of viral resistance to COVID-19 drug Paxlovid found
A new research provided evidence of viral resistance to Paxlovid among SARS-CoV-2 variants currently circulating globally, indicating that this stand-alone drug could soon become less effective in ...
- 2023 Hangover Cure Products Market Insightful Analysis of Top Companies, Future Projections, and Competitive Landscape
Global “Hangover Cure Products Market” Report Incorporate New Technologies: Stay Up-To-Date with Latest Technologies ...
- Condensation-Cure Silicone Mold Rubber Market Size By 2031
What is the Condensation-Cure Silicone Mold Rubber market growth? Condensation-Cure Silicone Mold Rubber Market Size is projected to Reach Multimillion USD by 2028, In comparison to 2023, at ...
- Track Covid-19 in California
Data is from the Centers for Disease Control and Prevention. The number of daily hospital admissions shows how many patients tested positive for Covid in hospitals and is more reliably reported ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”COVID-19 cure” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]